INMUNE BIO INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- INMUNE BIO INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2019-06-30 was 0.00 shares.
- INMUNE BIO INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2019-03-31 was 0.00 shares.
- INMUNE BIO INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 108.00K shares.
- INMUNE BIO INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2018 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2024-12-31 | 108.00K shares 10-K · filed 2025-03-27 | |
| 2019-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | |
| 2019-03-31 | 0.00 shares 10-Q · filed 2019-05-15 | |
| 2018-12-31 | 0.00 shares 10-K · filed 2019-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |